18F-FPYBF-2, a new F-18 labelled amyloid imaging PET tracer: biodistribution and radiation dosimetry assessment of first-in-man 18F-FPYBF-2 PET imaging.
Ryuichi NishiiTatsuya HigashiShinya KagawaChio OkuyamaYoshihiko KishibeMasaaki TakahashiTomoko OkinaNorio SuzukiHiroshi HasegawaYasuhiro NagahamaKoichi IshizuNaoya OishiHiroyuki KimuraHiroyuki WatanabeMasahiro OnoHideo SajiHiroshi YamauchiPublished in: Annals of nuclear medicine (2018)
The ED for the adult dosimetric model was similar to those of other agents used for amyloid PET imaging. The diagnostic dosage of 185-370 MBq of 18F-FPYBF-2 was considered to be acceptable for administration in patients as a diagnostic tool for the evaluation of AD.
Keyphrases
- pet imaging
- positron emission tomography
- end stage renal disease
- newly diagnosed
- ejection fraction
- emergency department
- radiation therapy
- chronic kidney disease
- computed tomography
- high resolution
- prognostic factors
- radiation induced
- patient reported outcomes
- pet ct
- patient reported
- childhood cancer
- fluorescence imaging
- clinical evaluation